menu
    • menu

    Company profile for Mozart Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Mozart is developing CD8 Treg cell modulators for the treatment of autoimmune and inflammatory diseases.Our advancing pipeline of first-in-class ‘CD8 Treg cell modulators’ are designed to restore durable immune balance and avert the progressive damage caused by pathogenic immune responses. To date, we’ve demonstrated that CD8 T regulatory cells are selective and function specifically to eliminate pathogenic CD4 T cells ...
    Mozart is developing CD8 Treg cell modulators for the treatment of autoimmune and inflammatory diseases.Our advancing pipeline of first-in-class ‘CD8 Treg cell modulators’ are designed to restore durable immune balance and avert the progressive damage caused by pathogenic immune responses. To date, we’ve demonstrated that CD8 T regulatory cells are selective and function specifically to eliminate pathogenic CD4 T cells and other pathogenic immune cells. The dysregulation of this T cell network is a root cause for the onset and severity of autoimmune and inflammatory disease and pathology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mozart TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    410 West Harrison Street, Suite 150, Seattle, WA 98119
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.mozart-tx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mozart Therapeutics Presents MTX-101 Data for Type 1 Diabetes
    Mozart Therapeutics Presents MTX-101 Data for Type 1 Diabetes

    05 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mozart-therapeutics-announces-podium-presentation-at-immunology-of-diabetes-congress-shows-potential-for-lead-program-mtx-101-to-restore-insulin-production-in-type-1-diabetes-302296311.html

    PR NEWSWIRE
    05 Nov 2024
    Share Share
    Mozart Therapeutics Doses First Cohort In Phase 1a/b Trial Of MTX-101
    Mozart Therapeutics Doses First Cohort In Phase 1a/b Trial Of MTX-101

    17 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mozart-therapeutics-doses-first-cohort-of-participants-in-phase-1ab-clinical-trial-of-mtx101-in-development-for-treatment-of-autoimmune-diseases-302173782.html

    PR NEWSWIRE
    17 Jun 2024
    Share Share
    Mozart Therapeutics Raises $25 Million in Expanded Series A Financing
    Mozart Therapeutics Raises $25 Million in Expanded Series A Financing

    07 Jun 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mozart-therapeutics-raises-25-million-in-expanded-series-a-financing-to-support-clinical-development-of-first-in-class-cd8-treg-modulators-for-the-treatment-of-autoimmune-diseases-301844098.html

    PR NEWSWIRE
    07 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search